Viana Taveira Michelle Ribeiro, Lima Luciana Santana, de Araújo Cláudia Corrêa, de Mello Maria Júlia Gonçalves
Instituto de Medicina Integral Prof. Fernando Figueira-IMIP, Recife, Pernambuco, Brazil.
Pediatr Blood Cancer. 2017 Feb;64(2):336-342. doi: 10.1002/pbc.26225. Epub 2016 Sep 26.
Totally implantable venous access ports (TIVAPs) are used for prolonged central venous access, allowing the infusion of chemotherapy and other fluids and improving the quality of life of children with cancer. TIVAPs were developed to reduce the infection rates associated with central venous catheters; however, infectious events remain common and have not been fully investigated in pediatric oncology patients.
A retrospective cohort was formed to investigate risk factors for central line-associated bloodstream infection (CLABSI) in pediatric cancer patients. Sociodemographic, clinical, and TIVAP insertion-related variables were evaluated, with the endpoint being the first CLABSI. A Kaplan-Meier analysis was performed to determine CLABSI-free catheter survival.
Overall, 188 children were evaluated over 77,541 catheter days, with 94 being diagnosed with CLABSI (50%). Although coagulase-negative staphylococci were the pathogens most commonly isolated, Gram-negative microorganisms (46.8%) were also prevalent. In the multivariate analysis, factors that increased the risk for CLABSI were TIVAP insertion prior to chemotherapy (risk ratio [RR] = 1.56; P < 0.01), white blood cell count less than 1,000 mm on the day of implantation (RR = 1.64; P < 0.01), and chronic malnutrition (RR = 1.41; P < 0.05). Median time without CLABSI following TIVAP insertion was 74.5 days.
Risk factors for CLABSI in pediatric cancer patients with a TIVAP may be related to the severity of the child's condition at catheter insertion. Insertion of the catheter before chemotherapy and unfavorable conditions such as malnutrition and bone marrow aplasia can increase the risk of CLABSI. Protocols must be revised and surveillance increased over the first 10 weeks of treatment.
完全植入式静脉输液港(TIVAPs)用于长期中心静脉通路,可进行化疗和其他液体输注,改善癌症患儿的生活质量。开发TIVAPs旨在降低与中心静脉导管相关的感染率;然而,感染事件仍然常见,且在儿科肿瘤患者中尚未得到充分研究。
形成一个回顾性队列,以调查儿科癌症患者中心静脉导管相关血流感染(CLABSI)的危险因素。评估社会人口统计学、临床和TIVAP插入相关变量,终点为首次发生CLABSI。进行Kaplan-Meier分析以确定无CLABSI的导管存活情况。
总体而言,在77541个导管日期间对188名儿童进行了评估,其中94名被诊断为CLABSI(50%)。虽然凝固酶阴性葡萄球菌是最常分离出的病原体,但革兰氏阴性微生物(46.8%)也很普遍。在多变量分析中,增加CLABSI风险的因素包括化疗前插入TIVAP(风险比[RR]=1.56;P<0.01)、植入当天白细胞计数低于1000/mm(RR=1.64;P<0.01)和慢性营养不良(RR=1.41;P<0.05)。TIVAP插入后无CLABSI的中位时间为74.5天。
患有TIVAP的儿科癌症患者发生CLABSI的危险因素可能与导管插入时患儿病情的严重程度有关。化疗前插入导管以及营养不良和骨髓抑制等不利情况会增加CLABSI的风险。必须修订治疗方案并加强治疗前10周的监测。